id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1235-0007,FDA,FDA-2012-E-1235,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-03-10T04:00:00Z,2015,3,2015-03-10T04:00:00Z,,2015-03-10T14:37:56Z,,0,0,0900006481a382b6
FDA-2012-E-1235-0006,FDA,FDA-2012-E-1235,"Determination of Regulatory Review Period for Purposes of Patent
Extension; PERJETA",Notice,General Notice,2014-05-19T04:00:00Z,2014,5,2014-05-19T04:00:00Z,,2014-05-19T13:59:09Z,2014-11515,0,0,0900006481702f8f
FDA-2012-E-1235-0005,FDA,FDA-2012-E-1235,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2014-05-02T19:10:42Z,,0,0,09000064816de817
FDA-2012-E-1235-0004,FDA,FDA-2012-E-1235,Letter from U.S. Patent and Trademark Office  to FDA CDER,Other,Letter(s),2014-03-29T04:00:00Z,2014,3,2014-03-29T04:00:00Z,,2014-03-30T04:06:48Z,,0,0,090000648168f912
FDA-2012-E-1235-0003,FDA,FDA-2012-E-1235,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2013-02-04T05:00:00Z,2013,2,2013-02-04T05:00:00Z,,2024-03-15T11:50:57Z,,0,0,09000064811e57f9
FDA-2012-E-1235-0002,FDA,FDA-2012-E-1235,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-12-28T05:00:00Z,2012,12,2012-12-28T05:00:00Z,,2012-12-28T14:01:20Z,,0,0,090000648119d26b
FDA-2012-E-1235-0001,FDA,FDA-2012-E-1235,"Genentech, Inc. (Morrison & Foerster LLP) - Patent Extension Application",Other,Application,2012-12-28T05:00:00Z,2012,12,2012-12-28T05:00:00Z,,2012-12-28T14:01:19Z,,0,0,090000648119d269